JP6675307B2 - 持続的薬物送達インプラントによる眼の状態の治療の方法 - Google Patents
持続的薬物送達インプラントによる眼の状態の治療の方法 Download PDFInfo
- Publication number
- JP6675307B2 JP6675307B2 JP2016530991A JP2016530991A JP6675307B2 JP 6675307 B2 JP6675307 B2 JP 6675307B2 JP 2016530991 A JP2016530991 A JP 2016530991A JP 2016530991 A JP2016530991 A JP 2016530991A JP 6675307 B2 JP6675307 B2 JP 6675307B2
- Authority
- JP
- Japan
- Prior art keywords
- implant
- biodegradable
- plga
- bioerodible
- eye
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts or implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361904887P | 2013-11-15 | 2013-11-15 | |
| US61/904,887 | 2013-11-15 | ||
| PCT/US2014/065804 WO2015073895A1 (en) | 2013-11-15 | 2014-11-14 | Methods of treatment of ocular conditions with a sustained drug delivery implant |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019225503A Division JP7022735B2 (ja) | 2013-11-15 | 2019-12-13 | 持続的薬物送達インプラントによる眼の状態の治療の方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016538292A JP2016538292A (ja) | 2016-12-08 |
| JP2016538292A5 JP2016538292A5 (https=) | 2019-06-20 |
| JP6675307B2 true JP6675307B2 (ja) | 2020-04-01 |
Family
ID=52001114
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016530991A Active JP6675307B2 (ja) | 2013-11-15 | 2014-11-14 | 持続的薬物送達インプラントによる眼の状態の治療の方法 |
| JP2019225503A Active JP7022735B2 (ja) | 2013-11-15 | 2019-12-13 | 持続的薬物送達インプラントによる眼の状態の治療の方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019225503A Active JP7022735B2 (ja) | 2013-11-15 | 2019-12-13 | 持続的薬物送達インプラントによる眼の状態の治療の方法 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20150140062A1 (https=) |
| EP (2) | EP3714875A1 (https=) |
| JP (2) | JP6675307B2 (https=) |
| KR (3) | KR20240058976A (https=) |
| CN (1) | CN105764517A (https=) |
| AU (4) | AU2014348369B2 (https=) |
| CA (1) | CA2929689A1 (https=) |
| CL (1) | CL2016001167A1 (https=) |
| CY (1) | CY1123344T1 (https=) |
| DK (1) | DK3068403T3 (https=) |
| ES (1) | ES2819215T5 (https=) |
| HU (1) | HUE050913T2 (https=) |
| IL (2) | IL245548A0 (https=) |
| MX (2) | MX2016006334A (https=) |
| MY (1) | MY176039A (https=) |
| NZ (1) | NZ719953A (https=) |
| PH (1) | PH12016500869A1 (https=) |
| PL (1) | PL3068403T3 (https=) |
| PT (1) | PT3068403T (https=) |
| RU (1) | RU2690841C1 (https=) |
| SG (1) | SG10201809363SA (https=) |
| SI (1) | SI3068403T1 (https=) |
| UA (1) | UA122117C2 (https=) |
| WO (1) | WO2015073895A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3324944A4 (en) * | 2015-07-23 | 2019-04-03 | Aerie Pharmaceuticals, Inc. | INTRAVITREAL AGGREGATION SYSTEMS FOR THE TREATMENT OF EYE DISEASE |
| JP2019534063A (ja) | 2016-09-02 | 2019-11-28 | エンビシャ セラピューティクス インコーポレイテッド | インプラントアプリケータ |
| US11690806B2 (en) | 2018-05-24 | 2023-07-04 | Celanese Eva Performance Polymers Llc | Implantable device for sustained release of a macromolecular drug compound |
| KR20260007295A (ko) | 2018-05-24 | 2026-01-13 | 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 | 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치 |
| US11689849B2 (en) | 2018-05-24 | 2023-06-27 | Nureva, Inc. | Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones |
| CN118718181A (zh) | 2019-06-05 | 2024-10-01 | 里珍纳龙药品有限公司 | 用于精确剂量递送的装置及方法 |
| CA3174217A1 (en) * | 2020-07-16 | 2022-01-20 | Ocular Therapeutix, Inc. | Ocular insert containing a glucocorticoid |
| BR112023022439A2 (pt) | 2021-04-26 | 2023-12-26 | Celanese Eva Performance Polymers Llc | Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6726918B1 (en) | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
| AU2002236495B2 (en) | 2000-11-29 | 2006-05-11 | Allergan, Inc. | Intraocular implants for preventing transplant rejection in the eye |
| US20050048099A1 (en) * | 2003-01-09 | 2005-03-03 | Allergan, Inc. | Ocular implant made by a double extrusion process |
| US8685435B2 (en) * | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
| US8119154B2 (en) | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| US20050244500A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intravitreal implants in conjuction with photodynamic therapy to improve vision |
| US20050244469A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| US20090082321A1 (en) * | 2007-09-21 | 2009-03-26 | Allergan, Inc. | Steroid containing drug delivery systems |
| CN103402582A (zh) * | 2011-02-11 | 2013-11-20 | 普西维达公司 | 使用抗水肿疗法治疗黄斑水肿的方法 |
-
2014
- 2014-11-14 CA CA2929689A patent/CA2929689A1/en active Pending
- 2014-11-14 RU RU2016119132A patent/RU2690841C1/ru active
- 2014-11-14 PT PT148057680T patent/PT3068403T/pt unknown
- 2014-11-14 PL PL14805768T patent/PL3068403T3/pl unknown
- 2014-11-14 SI SI201431652T patent/SI3068403T1/sl unknown
- 2014-11-14 WO PCT/US2014/065804 patent/WO2015073895A1/en not_active Ceased
- 2014-11-14 EP EP20173457.1A patent/EP3714875A1/en active Pending
- 2014-11-14 NZ NZ719953A patent/NZ719953A/en not_active IP Right Cessation
- 2014-11-14 KR KR1020247013455A patent/KR20240058976A/ko not_active Ceased
- 2014-11-14 CN CN201480062403.7A patent/CN105764517A/zh active Pending
- 2014-11-14 EP EP14805768.0A patent/EP3068403B2/en active Active
- 2014-11-14 KR KR1020227018854A patent/KR20220082934A/ko not_active Ceased
- 2014-11-14 MX MX2016006334A patent/MX2016006334A/es unknown
- 2014-11-14 US US14/542,189 patent/US20150140062A1/en not_active Abandoned
- 2014-11-14 JP JP2016530991A patent/JP6675307B2/ja active Active
- 2014-11-14 KR KR1020167015466A patent/KR102475746B1/ko active Active
- 2014-11-14 HU HUE14805768A patent/HUE050913T2/hu unknown
- 2014-11-14 AU AU2014348369A patent/AU2014348369B2/en active Active
- 2014-11-14 UA UAA201605224A patent/UA122117C2/uk unknown
- 2014-11-14 ES ES14805768T patent/ES2819215T5/es active Active
- 2014-11-14 SG SG10201809363SA patent/SG10201809363SA/en unknown
- 2014-11-14 DK DK14805768.0T patent/DK3068403T3/da active
- 2014-11-14 MY MYPI2016000899A patent/MY176039A/en unknown
-
2016
- 2016-05-09 IL IL245548A patent/IL245548A0/en unknown
- 2016-05-11 PH PH12016500869A patent/PH12016500869A1/en unknown
- 2016-05-13 MX MX2022002306A patent/MX2022002306A/es unknown
- 2016-05-13 CL CL2016001167A patent/CL2016001167A1/es unknown
-
2019
- 2019-12-13 JP JP2019225503A patent/JP7022735B2/ja active Active
-
2020
- 2020-06-30 AU AU2020204362A patent/AU2020204362A1/en not_active Abandoned
- 2020-09-14 CY CY20201100867T patent/CY1123344T1/el unknown
-
2022
- 2022-02-23 IL IL290837A patent/IL290837A/en unknown
- 2022-06-29 AU AU2022204607A patent/AU2022204607A1/en not_active Abandoned
-
2024
- 2024-08-09 AU AU2024205640A patent/AU2024205640B2/en active Active
-
2025
- 2025-02-21 US US19/060,301 patent/US20250319031A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7022735B2 (ja) | 持続的薬物送達インプラントによる眼の状態の治療の方法 | |
| Gaballa et al. | Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives | |
| JP6132964B2 (ja) | 萎縮性加齢性黄斑変性の処置方法 | |
| JP5696121B2 (ja) | α−２アドレナリン受容体アゴニスト含有生分解性眼内インプラント | |
| Manickavasagam et al. | Critical assessment of implantable drug delivery devices in glaucoma management | |
| de Oliveira Dias et al. | New drugs and new posterior delivery methods in CME | |
| Suresh et al. | Ocular implants as drug delivery device in opthalmic therapeutics: An overview | |
| HK40038783A (en) | Methods of treatment of ocular conditions with a sustained drug delivery implant | |
| HK1228770A1 (en) | Methods of treatment of ocular conditions with a sustained drug delivery implant | |
| HK1228770B (en) | Methods of treatment of ocular conditions with a sustained drug delivery implant | |
| Ahuja et al. | Post-operative assesment of single subconjunctival triamcinolone acetate injection vs topical corticosteroid in cataract surgery: A prospective control study | |
| Lee et al. | Posterior subtenon triamcinolone acetonide in gas-filled eyes as an adjunctive treatment for complicated proliferative diabetic retinopathy | |
| Augustin et al. | Suprachoroidal drug delivery–a new approach for the treatment of severe macular diseases | |
| Jalkh et al. | One Intravitreal Dexamethasone Implant versus Multiple Intravitreal Injections of Triamcinolone Acetonide for Post-Surgical Macular Edema: Efficacy and Safety | |
| Barman et al. | Sustained drug delivery in the posterior segments of the eye | |
| Stanojlović et al. | NECROTISING SCLERITIS AND PERIPHERAL ULCERATIVE KERATITIS ASSOCIATED WITH GRANULOMATOSIS WITH POLYANGIITIS (WEGENER’S GRANULOMATOSIS) OPERACIJA KATARAKTE KOD PACIJENTA SA OBOSTRANIM NEKROTIZUJUĆIM SKLERITISOM I PERIFERNIM ULCEROZNIM | |
| EL-Kasaby | Impact of Intravitreal Dexamethasone Implant (Ozurdex) in the Treatment of Persistent Non Tractional Diabetic Macular Edema | |
| HK1183436B (zh) | 用前房内比马前列素植入物的眼内压降低 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171114 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180907 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181112 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190212 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190412 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190513 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20190513 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190815 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191213 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20191223 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200217 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200310 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6675307 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |